News & Views

Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.

  • Subscribe to Nature Reviews Nephrology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).

  2. 2.

    et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).

  3. 3.

    et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

  4. 4.

    et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

  5. 5.

    et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).

  6. 6.

    et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 48, 1218–1225 (2017).

  7. 7.

    et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 12 (2001).

  8. 8.

    et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 12 (2001).

  9. 9.

    Adenosine A1 receptor antagonists in clinical research and development. Kidney Int. 78, 438–445 (2010).

  10. 10.

    et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 89, 1049–1061 (2016).

Download references

Author information


  1. Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410013, China.

    • Berthold Hocher
  2. Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal-Potsdam, Germany.

    • Oleg Tsuprykov


  1. Search for Berthold Hocher in:

  2. Search for Oleg Tsuprykov in:

Competing interests

B.H. is a consultant for Boehringer Ingelheim on the development of dipeptidyl peptidase 4 (DPP4) inhibitors and has received research funding from this company for investigation of the renal effects of the DPP4 inhibitor linagliptin. O.T. declares no competing interests.

Corresponding author

Correspondence to Berthold Hocher.